Cargando…

Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?

SIMPLE SUMMARY: Lung cancer is the leading cause of cancer-related death worldwide according to the World Health Organization. Non-small cell lung cancer makes up the majority of cases. Immunotherapy with immune checkpoint inhibitors and targeted therapy with tyrosine kinase inhibitors and other mol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reyes, Amanda, Pharaon, Rebecca, Mohanty, Atish, Massarelli, Erminia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296730/ https://www.ncbi.nlm.nih.gov/pubmed/37370772 http://dx.doi.org/10.3390/cancers15123162

Ejemplares similares

Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression
por: Reyes, Amanda, et al.
Publicado: (2022)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Biomarkers in immunotherapy: literature review and future directions
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
por: Roosan, Moom R., et al.
Publicado: (2021)

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer
por: Ramisetty, Sravani, et al.
Publicado: (2023)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions
por: Pathak, Ranjan, et al.
Publicado: (2021)

Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report
por: Pharaon, Rebecca R., et al.
Publicado: (2022)

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
por: Nguyen, Toan D., et al.
Publicado: (2023)

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
por: Koster, Kira-Lee, et al.
Publicado: (2022)

Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors
por: Guo, Linlin, et al.
Publicado: (2023)

An Analysis and Comparison of Survival and Functional Outcomes in Oropharyngeal Squamous Cell Carcinoma Patients Treated with Concurrent Chemoradiation Therapy within City of Hope Cancer Center Sites
por: Pharaon, Rebecca, et al.
Publicado: (2020)

A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer
por: Mohanty, Atish, et al.
Publicado: (2020)

Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy
por: Nam, Arin, et al.
Publicado: (2021)

Those ADCs
Publicado: (1971)

A rare case of parotid gland lipoma arising from the deep lobe of the parotid gland
por: Paparo, Francesco, et al.
Publicado: (2016)

A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer
por: Mohanty, Atish, et al.
Publicado: (2020)

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
por: Zhao, Dan, et al.
Publicado: (2021)

Low-Grade Fibromyxoid Sarcoma Featuring an Unusual EWSR1-CREB3L2 Gene Fusion: Report of a Rare Case Arising in the Parotid Gland
por: Alayed, Doaa M., et al.
Publicado: (2022)

ADC : analog-to-digital converter reference manual.

Precision medicine and actionable alterations in lung cancer: A single institution experience
por: Mambetsariev, Isa, et al.
Publicado: (2020)

The Chemistry Behind ADCs
por: Kostova, Vesela, et al.
Publicado: (2021)

Evaluating the Scope of Malignant Bone Tumor Using ADC Measurement on ADC Map
por: Chen, Haisong, et al.
Publicado: (2019)

BEAT(® )the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs
por: Moretti, Pierre, et al.
Publicado: (2013)

Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability
por: Lambregts, Doenja M. J., et al.
Publicado: (2011)

Integration of artificial intelligence in lung cancer: Rise of the machine
por: Ladbury, Colton, et al.
Publicado: (2023)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
por: Ordóñez-Reyes, Camila, et al.
Publicado: (2022)

Endometrial Cancer Staging: Is There Value in ADC?
por: Moreira, Ana Sofia Linhares, et al.
Publicado: (2023)

LAr LTDB ADC’s calibration
por: Estevam De Paula, Rodrigo
Publicado: (2021)

Preamplifier/Shapers & ADC for Calorimeters
por: Schwemling, Philippe
Publicado: (2018)

Current ADC Linker Chemistry
por: Jain, Nareshkumar, et al.
Publicado: (2015)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Diffusion-Weighted Imaging for the Discrimination of Benign and Malignant Breast Masses; Utility of ADC and Relative ADC
por: Yılmaz, Ebru, et al.
Publicado: (2018)

Differentiation of Benign and Malignant Breast Lesions Using ADC Values and ADC Ratio in Breast MRI
por: Tsvetkova, Silvia, et al.
Publicado: (2022)

Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review
por: Khosla, Atulya Aman, et al.
Publicado: (2023)

Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?
por: Zheng, Songmao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cgo1cqqp1j7sabjis14a2qee4c